Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient! | Zendy

Tanya Naskova Popova | Zendy; Atanass Radinov | Zendy; Konstantin Stavrov | Zendy; Ivanka Temelkova | Zendy; Ivan Terziev | Zendy; Ilia Lozev | Zendy; Detelina Lukanova | Zendy; Hristo Mangarov | Zendy; Uwe Wollina | Zendy; Georgi Tchernev | Zendy

Open Access

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!

Author(s) -

Tanya Naskova Popova,

Atanass Radinov,

Konstantin Stavrov,

Ivanka Temelkova,

Ivan Terziev,

Ilia Lozev,

Detelina Lukanova,

Hristo Mangarov,

Uwe Wollina,

Georgi Tchernev

Publication year - 2018

Publication title -

open access macedonian journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.288

H-Index - 17

ISSN - 1857-9655

DOI - 10.3889/oamjms.2018.289

Subject(s) - brentuximab vedotin , medicine , anaplastic large cell lymphoma , cd30 , lymphoma , oncology , large cell lymphoma , dermatology

Modern drugs could sometimes be a good solution even to problematic patients. The cutaneous and systemic forms of the CD30 positive anaplastic large T-cell lymphoma could often be described as a suitable target for therapy with Brentuximab vedotin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research